REVOLUTION Medicines(RVMDW)

Focus: REVOLUTION Medicines is a publicly traded oncology-focused small molecule biotech founded in 2023, headquartered in Redwood City, CA, with a pipeline spanning colorectal, lung, pancreatic cancers and CNS indications. The company is in early-to-mid clinical development with multiple Phase 1-3 programs.

Oncology Neurology Gastroenterology Respiratory

Profile data last refreshed 45m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$1B

Open Jobs

200+119 this month

Hot — 431 jobs added in 30d

Net +119 (431 new, 312 removed). Aggressive expansion phase.

Should You Work at REVOLUTION Medicines?

AI assessment

High-growth opportunity for risk-tolerant professionals seeking early-stage impact, but severe burn rate and lack of commercial validation make this a bet-the-company scenario with 1-2 year decision point.

Why Work Here

225 active job openings signal aggressive expansion across R&D, regulatory, and commercialization functions—rare growth opportunity for a 2023-founded biotech

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$12M

Pipeline & Clinical Trials

RMC-9805

Non-small Cell Lung Cancer (NSCLC)

PHASE_1

Clinical Trials (1)

NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Phase 1

Help build intelligence for REVOLUTION Medicines

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong cash position of $696M (FY2025) provides runway and reduces near-term extinction risk, enabling sustained hiring and program advancement

Four Phase 3 programs (daraxonrasib in NSCLC/pancreatic, RMC-6236 in pancreatic) offer near-term catalysts and proof-of-concept milestones within 1-2 years

Diverse therapeutic footprint (oncology, neurology, gastroenterology, respiratory) reduces single-indication risk and provides cross-functional learning

Watch Out For

Burn rate is extreme: $436M net loss on only $12M revenue (FY2025), with R&D spend of $423M—cash runway is ~1.5 years at current burn, creating restructuring risk if Phase 3s fail
Founded in 2023 with no approved products, zero publications, and no commercial infrastructure maturity; career growth depends entirely on pipeline success
Pipeline is crowded in competitive NSCLC/KRAS space (Elironrasib, RMC-6291, RMC-9805, daraxonrasib) with limited differentiation signals visible in public data
Minimal publicly available clinical data, recent news, or milestone transparency raises visibility risk for near-term setbacks

Generated by Claude from REVOLUTION Medicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

RMC-5552

Glioblastoma

PHASE_1

Clinical Trials (1)

NCT05557292RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Phase 1

RMC-4630

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT03634982Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1

RMC-6291

Non-Small Cell Lung Cancer (NSCLC)

PHASE_1

Clinical Trials (1)

NCT05462717Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Phase 1

RMC-5552

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT04774952Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1

RMC-5127

Non-small Cell Lung Cancer (NSCLC)

PHASE_1

Clinical Trials (1)

NCT07349537Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Phase 1

TNG462

PDAC

PHASE_1_2

Clinical Trials (1)

NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Phase 1/2

RMC-6291

Non-Small Cell Lung Cancer, NSCLC

PHASE_1_2

Clinical Trials (1)

NCT06162221Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Phase 1/2

RMC-6236

Colorectal Cancer

PHASE_1_2

Clinical Trials (1)

NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2

Elironrasib

Non-Small Cell Lung Cancer (NSCLC)

PHASE_1_2

Clinical Trials (1)

NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Phase 1/2

RMC-6236

Non-small Cell Lung Cancer (NSCLC)

PHASE_1_2

Clinical Trials (1)

NCT05379985Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Phase 1/2

Daraxonrasib

Advanced Solid Tumors

PHASE_1_2

Clinical Trials (1)

NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1/2

RMC-4630

Solid Tumor

PHASE_1_2

Clinical Trials (1)

NCT03989115Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Phase 1/2

Vociprotafib

Metastatic Neoplasm

PHASE_1_2

Clinical Trials (1)

NCT04418661Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Phase 1/2

RMC-4630

Non-Small Cell Lung Cancer

PHASE_2

Clinical Trials (1)

NCT05054725Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Phase 2

RMC-6236

Pancreatic Cancer

PHASE_3

Clinical Trials (1)

NCT06625320Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3

daraxonrasib

Pancreatic Cancer

PHASE_3

Clinical Trials (1)

NCT07252232Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3

daraxonrasib

NSCLC (Non-small Cell Lung Cancer)

PHASE_3

Clinical Trials (2)

NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Phase 3

NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 3

Interview Prep Quick Facts

Founded: 2023

Portfolio: 19 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Open Roles: 200 active jobs

Therapeutic Area Focus

Oncology

19 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$12M67%

R&D Spend

$423M(3654%)67%

Net Income

-$436M

Hiring Trend

Actively Hiring

200

Open Roles

+51

Added

-8

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

REVOLUTION Medicines(RVMDW)

Should You Work at REVOLUTION Medicines?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · REVOLUTION Medicines(10)

Open Jobs (200)

Director, Medical Project Management

Corporate Paralegal, SEC Reporting & Corporate Governance

Associate Director, Clinical Operations Enablement & Knowledge Systems

Director, GLP Quality Assurance

Executive Director, Quality, Europe

Executive Director, Quality, Europe

Associate Director, Qualified Person, Europe

Senior Director, Medical Affairs Lung, Europe

Senior Director, Payor and Health Systems Liaison, West

Senior Director, Payor and Health Systems Liaison, East

Project Coordinator

Scientist II, Cancer Pharmacology, Translational Research

Senior Manager, Compliance - Field Commercialization (West)

Scientist II, Structural Biology

Senior Medical Director, Early-Stage Clinical Development

Associate Director, Global Quality System & Compliance

Director, IS Governance, Risk and Compliance

Director, Global Forecasting

Associate Director, Regulatory Operations, Europe

Senior Director, Country Manager, Switzerland

Vice President Sales and Field Team - NSCLC

Director, HEOR/RWE - Lung

Associate Director, Clinical Operations Compliance & Training

Senior Director, Medical Affairs, UK

Senior Director, Medical Affairs, Italy

Financials (FY2025)

Hiring Trend